These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37088371)

  • 1. Randomized controlled trial of omalizumab in treatment-resistant systemic and cutaneous mastocytosis (ROAM).
    McComish JS; Slade CA; Buizen L; Paul SK; Chatelier JW; Unglik G; Nicholls KA; Spriggs K; Chan SS; Godsell J; Auyeung P; Tan ZH; DeLuca J; Patel M; Kuek LE; Tran Y; Kern JS; Scardamaglia L; Varigos GA; Juneja S; Grabek JA; Christie M; Mackay GA; Douglass JA
    J Allergy Clin Immunol Pract; 2023 Jul; 11(7):2248-2250.e3. PubMed ID: 37088371
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair
    Hughes JDM; Olynyc T; Chapdelaine H; Segal L; Miedzybrodzki B; Ben-Shoshan M
    Clin Exp Dermatol; 2018 Jul; 43(5):573-576. PubMed ID: 29451318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study).
    Distler M; Maul JT; Steiner UC; Jandus P; Kolios AGA; Murer C; Graf N; Seebach JD; Pichler WJ; Navarini AA; French LE; Helbling A; Schmid-Grendelmeier P
    Dermatology; 2020; 236(6):529-539. PubMed ID: 31958790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-year follow-up of omalizumab therapy for anaphylaxis in 2 patients with systemic mastocytosis.
    Constantine GM; Bressler PB; Petroni D; Metcalfe DD; Carter MC
    J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1314-1316. PubMed ID: 30149096
    [No Abstract]   [Full Text] [Related]  

  • 5. Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations.
    Broesby-Olsen S; Vestergaard H; Mortz CG; Jensen B; Havelund T; Hermann AP; Siebenhaar F; Møller MB; Kristensen TK; Bindslev-Jensen C;
    Allergy; 2018 Jan; 73(1):230-238. PubMed ID: 28662309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term omalizumab treatment in an adolescent with cutaneous mastocytosis.
    Matito A; Blázquez-Goñi C; Morgado JM; Alvarez-Twose I; Mollejo M; Sánchez-Muñoz L; Escribano L
    Ann Allergy Asthma Immunol; 2013 Nov; 111(5):425-6. PubMed ID: 24125156
    [No Abstract]   [Full Text] [Related]  

  • 7. Successful treatment with Omalizumab of a child affected by Systemic Mastocytosis: clinical and biological implications.
    Bossi G; Brazzelli V; De Amici M; Pietra D; Raviola C; Naso M; Regalbuto C; Boselli F; Fortina V; Marseglia GL
    Ital J Pediatr; 2023 Jan; 49(1):6. PubMed ID: 36639823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of omalizumab in Cutaneous Mastocytosis: A case series.
    Hinojosa T; Lewis DJ; Vangipuram R; Safeer L; Mui UN; Haley C; Konoplev S; Tyring SK
    Dermatol Ther; 2019 May; 32(3):e12848. PubMed ID: 30697883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response to omalizumab in patients with hereditary α-tryptasemia.
    Mendoza Alvarez LB; Barker R; Nelson C; DiMaggio T; Stone KD; Milner JD; Rosenthal JA; Petroni DH; Glover SC; Lyons JJ
    Ann Allergy Asthma Immunol; 2020 Jan; 124(1):99-100.e1. PubMed ID: 31605754
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective Response to Omalizumab in a Patient With Concomitant ncMCAS and POTS: What Does it Teach us About the Underlying Disease?
    Kacar M; Denman S; Savic S
    J Investig Allergol Clin Immunol; 2018 Aug; 28(4):261-263. PubMed ID: 30073959
    [No Abstract]   [Full Text] [Related]  

  • 11. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient.
    Douglass JA; Carroll K; Voskamp A; Bourke P; Wei A; O'Hehir RE
    Allergy; 2010 Jul; 65(7):926-7. PubMed ID: 19889117
    [No Abstract]   [Full Text] [Related]  

  • 12. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.
    Carter MC; Robyn JA; Bressler PB; Walker JC; Shapiro GG; Metcalfe DD
    J Allergy Clin Immunol; 2007 Jun; 119(6):1550-1. PubMed ID: 17481708
    [No Abstract]   [Full Text] [Related]  

  • 13. Suplatast tosilate for treating cutaneous mastocytosis.
    Yasudo H; Ando T; Hiwatari M; Oka A
    Pediatr Dermatol; 2015; 32(3):e118-9. PubMed ID: 25779849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omalizumab induced remission of idiopathic anaphylaxis in a patient suffering from indolent systemic mastocytosis.
    Kibsgaard L; Skjold T; Deleuran M; Vestergaard C
    Acta Derm Venereol; 2014 May; 94(3):363-4. PubMed ID: 24162824
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab as a desensitizing agent and treatment in mastocytosis: a review of the literature and case report.
    Sokol KC; Ghazi A; Kelly BC; Grant JA
    J Allergy Clin Immunol Pract; 2014; 2(3):266-70. PubMed ID: 24811015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cladribine improves cutaneous manifestations, Dermatology Life Quality Index, and Mastocytosis Quality of Life of patients with mastocytosis.
    Bugaut H; Maillard H; Jacobzone C; Haddad N; Le Pelletier F; Charlotte F; Arock M; Dubreuil P; Bulai Livideanu C; Hermine O; Barete S
    J Am Acad Dermatol; 2024 May; 90(5):1044-1046. PubMed ID: 38219804
    [No Abstract]   [Full Text] [Related]  

  • 17. Omalizumab in the treatment of adult patients with mastocytosis: A systematic review.
    Jendoubi F; Gaudenzio N; Gallini A; Negretto M; Paul C; Bulai Livideanu C
    Clin Exp Allergy; 2020 Jun; 50(6):654-661. PubMed ID: 32107810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mastocytosis: revisited with new cytogenetic data].
    Vaes M; Vereecken P; de Wind R; Andry G; Li R; Bron D
    Rev Med Brux; 2012; 33(1):12-21. PubMed ID: 22512145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS.
    Lemal R; Fouquet G; Terriou L; Vaes M; Livideanu CB; Frenzel L; Barete S; Canioni D; Lhermitte L; Rossignol J; Arock M; Dubreuil P; Lortholary O; Hermine O
    J Allergy Clin Immunol Pract; 2019; 7(7):2387-2395.e3. PubMed ID: 30954641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of omalizumab as a successful treatment for telangiectasia macularis eruptiva perstans.
    Mortimore AM; Barsoum R; Lambie D; McMeniman E
    Australas J Dermatol; 2022 Feb; 63(1):102-104. PubMed ID: 34314029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.